Botulinum toxin type A (Botox) — Mechanism of Action
Botulinum toxin A blocks acetylcholine release at peripheral cholinergic nerve terminals by cleaving SNAP‑25 after receptor-mediated endocytosis into the presynaptic terminal, producing a reversible chemodenervation and flaccid paralysis until new nerve terminals sprout. [1–1]
Molecular steps (highest-quality guideline evidence):
- Binding: Heavy chain binds receptors on cholinergic nerve terminals at the neuromuscular junction and other peripheral cholinergic sites. 1
- Internalization: Receptor-mediated endocytosis and translocation of the light chain into the cytosol. 1
- Catalysis: Zinc-endopeptidase (light chain) cleaves SNARE proteins; for serotype A, the target is SNAP‑25, blocking synaptic vesicle fusion. 1
- Functional effect: Inhibition of acetylcholine release from presynaptic motor neurons → localized flaccid paralysis. Recovery occurs over weeks–months via axonal sprouting/new terminal formation. 1
Distribution and central effects:
- Large molecular size prevents crossing the blood–brain barrier; direct CNS effects in humans are not documented. Possible axonal transport has not shown human CNS effects. 1
Nuances and caveats:
- All serotypes share this multi-step process but cleave different SNARE targets; type A’s severity and duration are among the greatest. 1
- Emerging research describes sensory and anti-nociceptive effects and actions beyond motor blockade, but the core and clinically decisive mechanism remains SNAP‑25 cleavage–mediated acetylcholine blockade. Prioritize guideline-described mechanism for clinical decision-making affecting morbidity, mortality, and quality of life. 2, 3